永顺生物
(920729)
| 流通市值：5.43亿 | | | 总市值：19.16亿 |
| 流通股本：7750.70万 | | | 总股本：2.73亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 87,485,096.54 | 47,452,322.97 | 238,174,536.39 | 179,973,670.63 |
| 营业收入 | 87,485,096.54 | 47,452,322.97 | 238,174,536.39 | 179,973,670.63 |
| 二、营业总成本 | 84,702,179.66 | 43,338,273.37 | 206,942,003.57 | 156,149,380.07 |
| 营业成本 | 39,908,984.03 | 18,577,801.7 | 101,297,830.8 | 72,850,682.03 |
| 税金及附加 | 1,342,347.29 | 750,379.37 | 1,888,618.23 | 1,418,537.96 |
| 销售费用 | 18,268,902.81 | 10,642,869.43 | 45,117,948.03 | 37,858,200.8 |
| 管理费用 | 15,251,320.45 | 7,522,284.34 | 38,929,384.8 | 28,766,106.97 |
| 研发费用 | 9,555,494.08 | 5,708,396.65 | 19,696,573.55 | 15,313,132.33 |
| 财务费用 | 375,131 | 136,541.88 | 11,648.16 | -57,280.02 |
| 其中:利息费用 | 10,363.52 | 5,396.29 | 59,145.8 | 112,902.85 |
| 其中:利息收入 | 511,350.69 | 235,137.62 | 282,147.17 | 52,309.13 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 63,829.96 | 63,829.96 | 196,719.6 | 151,707.7 |
| 加:投资收益 | 5,308,817.76 | 2,764,870.48 | 12,251,556.96 | 9,480,214.13 |
| 资产减值损失(新) | -3,220,552.27 | -1,673,008.6 | -1,428,271.68 | -1,431,018.33 |
| 信用减值损失(新) | -1,121,619.73 | -1,232,345.22 | 679,258.4 | -226,331.99 |
| 其他收益 | 2,748,692.89 | 1,341,473.91 | 3,358,574.25 | 2,258,267.51 |
| 四、营业利润 | 6,562,085.49 | 5,378,870.13 | 46,290,370.35 | 34,057,129.58 |
| 加:营业外收入 | 225,852.35 | 67,490 | 126,992.5 | 117,242.5 |
| 减:营业外支出 | 46,009.35 | 34,215.35 | 221,470.07 | 175,426.75 |
| 五、利润总额 | 6,741,928.49 | 5,412,144.78 | 46,195,892.78 | 33,998,945.33 |
| 减:所得税费用 | 327,326.81 | 329,045.97 | 4,937,915.16 | 3,715,122.06 |
| 六、净利润 | 6,414,601.68 | 5,083,098.81 | 41,257,977.62 | 30,283,823.27 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 6,414,601.68 | 5,083,098.81 | 41,257,977.62 | 30,283,823.27 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 6,414,601.68 | 5,083,098.81 | 41,257,977.62 | 30,283,823.27 |
| 扣除非经常损益后的净利润 | 184,988.79 | 1,984,976.23 | 29,696,026.3 | 21,514,608.39 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.02 | 0.15 | 0.11 |
| (二)稀释每股收益 | 0.02 | 0.02 | 0.15 | 0.11 |
| 九、综合收益总额 | 6,414,601.68 | 5,083,098.81 | 41,257,977.62 | 30,283,823.27 |
| 归属于母公司股东的综合收益总额 | 6,414,601.68 | 5,083,098.81 | 41,257,977.62 | 30,283,823.27 |
| 公告日期 | 2026-08-24 | 2026-04-28 | 2026-04-28 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |